06/12/2018 15:14:14

Beyond Celiac partners with imaware™ to expand use of at-home celiac disease testing for faster medical diagnosis

Philadelphia, PA, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Beyond Celiac today announced their newest partner, imaware™.  imaware™ is a unique at-home celiac disease screening and monitoring test that is highly accurate and provides actionable results for patients. Beyond Celiac is partnering with imaware™ to support the ambitious goal of dramatically reducing the number of individuals dealing with undiagnosed celiac disease by helping them more quickly take the steps needed for diagnosis.

“Celiac disease has long been plagued by low diagnosis rates. It is estimated that less than 20 percent of patients who have the condition know it,” noted Alice Bast, Beyond Celiac CEO. “We hear from our community that their doctors do not want to test them despite symptoms. The average delay in diagnosis is 6 to 10 years. It took me eight years to get diagnosed,” she added.

A study published recently in the United European Gastroenterology Journal concluded that patients whose diagnosis had been delayed for three years reported being sick more often, going to the doctor more frequently and using more drugs for indigestion and depression than those who were diagnosed more quickly.

“We believe that the imaware™ at-home celiac disease test will help reduce the number of undiagnosed people with celiac disease,” said Jani Tuomi, Chief Product Officer for imaware™. “An easy to use test, with easy to read results that are reviewed by a doctor, will dramatically reduce time to diagnosis. With a partner like Beyond Celiac, we will be able to better engage with the patient community to educate, screen, and ultimately help patients engage their doctors sooner for diagnosis.”

The imaware™ test measures the same antibodies to gluten as the tests that doctors use in their offices as the first step to diagnose celiac disease – anti-tissue transglutaminase (tTG) and deaminated gliadin peptide (DGP) tests. In the United States, definitive diagnosis of celiac disease requires a biopsy that shows intestinal damage in addition to the blood test.

Sold online only, the imaware™ test requires a finger prick and collection of a small amount of blood in a vial. Consumers then mail their sample back and receive their confidential test results via a secure portal in about a week. For results to be accurate, consumers need to be on a normal gluten-containing diet. The imaware™ at-home test for celiac disease is available at imaware.health for $165.00. Beyond Celiac will receive a portion of sales to support their ongoing initiatives to drive diagnosis, advance research and accelerate the discovery of new treatments and a cure. 

XXX

About Celiac Disease

Celiac disease is a serious, genetic, autoimmune disorder that affects an estimated 1 in 100 Americans, the vast majority of whom are still undiagnosed. The disease causes debilitating symptoms, and if left untreated, can lead to serious long-term health problems including infertility and some types of cancer.

About Beyond Celiac:

A 501(c)(3) non-profit organization, Beyond Celiac envisions a world in which people with celiac disease can live healthy lives free from social stigma and fear of gluten exposure – A world Beyond Celiac.

Attachment

Claire Baker

Beyond Celiac

215-325-1306 ext. 111

cbaker@beyondceliac.org

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Aug
VELO
Da flere skribenter stadig gerne vil beholde tråden for samling af de mange vigtige informationer o..
44
23 Aug
GEN
For Genmab investorer bliver september måned en hot affære - der kommer i hvert fald en stribe nyhed..
40
19 Aug
OMXC25
Endnu en dansk patriark er død. Ære være hans minde.
29
18 Aug
 
Da Berlingske Media for cirka 1 år siden overtog Euroinvestor for 23 mio kr, meddelte de, at nu skul..
22
21 Aug
I:NDX
Trump er en forretningsmand, der bevæger sig med en forretningsmands hastighed. Han er fløjtende lig..
21
22 Aug
 
Jeg synes hun gjorde det fremragende i sagen om Grønland og Trump.   Det vigtigste i en sådan situat..
20
20 Aug
VELO
Ny artikel på Medwatch:   15,5 pct. af amerikanske patienter, der får en nyretransplantation i dag, ..
20
18 Aug
VELO
Fra anden skribent i Veloxis FB gruppen: Børsen side 4, søndag den 18. august. Et uddrag fra e..
20
20 Aug
PNDORA
  har du læst regnskabet - de forventer at tjene 4 mia i 2019 i forhold til en værdi af selskabet på..
18
19 Aug
OMXC25
En fantastisk dygtig og sympatisk erhvervsmand.  Og en ægte patriot som også betalte sin skat med gl..
18

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Textron Inc. To Contact The Firm
2
Alleged breach of loan covenants - Company announcement No 13/2019
3
Mississippi Chef Wins $100,000 and is Crowned 7th World Food Champion
4
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Valaris plc To Contact The Firm
5
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In SAExploration Holdings, Inc. To Contact The Firm

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 August 2019 08:45:41
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB6 - 2019-08-25 09:45:41 - 2019-08-25 08:45:41 - 1000 - Website: OKAY